Mars, Sarah G. http://orcid.org/0000-0002-7109-8602
Koester, Kimberly A.
Ondocsin, Jeff
Mars, Valerie
Mars, Gerald
Ciccarone, Daniel
Funding for this research was provided by:
National Institute on Drug Abuse (DA037820)
National Institutes of Health UCSF-Gladstone Center for AIDS Research (P30AI027763)
Article History
Accepted: 8 January 2022
First Online: 23 February 2022
Declarations
:
: Dr. Daniel Ciccarone reports the following relevant financial relationships during the past 12 months: 1, he is a scientific advisor to Celero Systems and 2, he has been retained as an expert witness in ongoing prescription opioid litigation by Motley Rice, LLP. The remaining authors have no relevant financial or non-financial interests to disclose.
: The methodology of this study was approved by the Committee on Human Research of the University of California San Francisco, Institutional Review Board Number 18-27035.
: Informed consent was obtained from all individual participants included in the study and, where quotations have been used, for these to be published in a journal article.